A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
Apoptosis, or programmed cell death, is a tightly regulated biological process necessary for normal tissue maintenance and development. However, aberrations in apoptotic signaling networks are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback